EVMN
$23.33-0.23 (-0.98%)
Evommune, Inc.
Recent News
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Evommune has two autoimmune disorder treatments with blockbuster potential.
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success
Evommune, Luis Peña Joins Ashley Mastronardi on NYSE Live to Reveal What’s Behind Company’s Post-IPO Success
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement
Evommune (EVMN) has drawn fresh attention after reporting statistically strong Phase 2a results for its eczema drug candidate EVO301, alongside a US$125.3m private placement arranged at US$27.88 per share. See our latest analysis for Evommune. The strong Phase 2a update and the US$125.3m private placement arrive as Evommune’s short term share price return has accelerated, with a 1 day move of 13.24% and a 7 day share price return of 82.38%, contributing to an 82.38% year to date share price...